Vimta Labs Limited · NSE:VIMTALABS
Vimta Labs — Q3 FY2026 Earnings Presentation
32 slides from Vimta Labs's earnings presentation, Jan 28, 2026
Slide 1: SUJANI VASIREDDI Date:
https://vimta.com/investor- presentation/ Digitally signed by SUJANI SUJANI VASIREDDI VASIREDDI Date: 2026.01.28 15:13:27 +05'30'
Slide 2: Investor Presentation Q3 & 9M FY26
INVESTOR PRESENTATION Q3 & 9M FY26 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table of Contents
Table Of • Q3 & 9M FY26 Earnings Contents • Company Overview • Industry Landscape • Our Competitive Advantage • Way Forward 3
Slide 5: Q3 & 9M FY26 Earnings
Q3 & 9M FY26 Earnings Section • Q3 & 9M FY26 Highlights 01 • • Key Metrics: Q3 & 9M FY26 Profit & Loss Statement • Financial Track Record • Shareholding Pattern 4
Slide 6: Q3 FY26 Highlights
Q3 FY26 Highlights Rs 1,005 Mn Rs 344 Mn* Rs 234 Mn* Margin 34.3% Margin 23.3% Total Income EBITDA PBT Rs 3.96 Rs 248.3 Mn Rs 176 Mn* Margin 17.5% CAPEX (Cash EPS PAT Outflow) * Including exceptional item 5
Slide 7: 9M FY26 Highlights
9M FY26 Highlights Rs 3,043 Mn Rs 1,068 Mn* Rs 749 Mn* Margin 35.1% Margin 24.6% Total Income EBITDA PBT Rs 12.67 Rs 666.6 Mn Rs 564 Mn* Margin 18.5% Cash & Cash EPS PAT Equivalent # #Cash and Cash equivalents includes other bank balances * Including exceptional item 6
Slide 8: Key Metrics: Q3 FY26
Key Metrics: Q3 FY26 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 10.2% 0.4% 0.4% YoY YoY YoY 19.2% 19.1% 37.6% 35.3% 5 17.5% 34.3% 911 1,045 1005 343 369 344 175 199 176 3.9 4.5 4.0 0 Q3FY25 Q2FY26 Q3FY
Slide 9: Key Metrics: 9M FY26
Key Metrics: 9M FY26 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 20.7% 16.7% 16.4% YoY YoY YoY 40% 35% 30% 36.3% 35.1% 25% 19.2% 18.5% 20% 15% 2,521 3,043 915 1,068 484 564 10.9 12.7 10% 9MFY25 9MFY26 9
Slide 10: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q3 FY26 Q2 FY26 QoQ(%) Q3 FY25 YoY (%) 9M FY26 9M FY25 YoY (%) Revenue from Operations 986 1,018 899 2,980 2,495 Other Income 18 27 12 62 26 Total Income 1,005 1,045 -3.9% 911 10.2% 3,043 2,521 20.7% Material and Testing Costs 193 201 204 582 529 Cost of la
Slide 11: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA PAT & PAT Margin Margin 35% 19% 36% 31% 33% 17% 19% 29% 15% 15% 11.2% 25% 25.1% 46.3% CAGR 18% CAGR 4% 10% CAGR 1,837 2,115 2,797 3,216 2,923 3,482 3,043 330 538 817 984 977 1,262 1,068 214 413 482 488 668 564 68 FY20 FY
Slide 12: Shareholding Pattern
Shareholding Pattern Shareholding as on 31st December 2025 Share Information as on 31st December 2025 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 2,705.79 % free-float 64.10% Others Promoters 59.4% Free-float market cap (INR Cr) 1,734.47 35.9% Total Debt (INR Mn) 45.2 Cash & Cash Equi
Slide 13: Company Overview
Company Overview Section • Vimta at a Glance 02 • • Our Journey Our Offerings • Geographical Presence • Management 12
Slide 14: Vimta at a Glance
Vimta at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, sma
Slide 15: Our Journey
Our Journey Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & development 2024 600,000+ ft2 1300+ 492 M services; Food; Environment; Electronics Testing 3,216 M Analytical – Pharma, Biopharma & Food; Clinical 2015 400,000+ ft2 1000+ 580 M Research; Preclinical; C
Slide 16: Our Offerings
Our offerings Drug discovery and development services Food & Agri Testing Electronics & Electricals Testing Environment Testing & Consultancy 15
Slide 17: 1. Drug discovery and development services
1. Drug discovery and development services Offerings Pharma Analytical Clinical Research Preclinical Research Pharmaceuticals, Biologics, Medical Industry Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health Device, Agrochemical, Speciality Chemicals Accreditations & DCA, USFDA
Slide 18: 2. Food & Agri Testing
2. Food & Agri Testing Industry Food Manufacturing & Processing, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed No. of Locations 7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida) Accreditations & • FSSAI, ISO 17025, BIS, APEDA, EIC
Slide 19: 3. Electricals & Electronics Testing & Certification
3. Electricals & Electronics Testing & Certification Industry Aviation, Defense, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries No. of Locations 1 (Hyderabad) Accredit
Slide 20: 4. Environment Testing & Consultancy Services
4. Environment Testing & Consultancy Services Industry Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc. No. of Locations 4 (Hyderabad, Chennai, Kolkata and Noida) Accreditations & Regulatory • MoEF, ISO 17025, QCI/NABET, OSHAS 45000 Approvals • Post pro
Slide 21: Geographical Presence
Geographical Presence Food Environment Electrical and Electronics Hyderabad Hyderabad Hyderabad Ahmedabad Chennai Noida Noida Mumbai (NFL) Kolkata Nashik Bengaluru Nellore Food Electronics & Electrical Hyderabad (Headquarters) Pharma Environment 20
Slide 22: Key Management Team
Key Management Team Harriman Vungal S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Siva Kambhampati Executive Director - Executive Chairman Managing Director Executive Director Chief Financial Officer Operations • Dr. S P Vasireddi is a Scientist – • Harita has close to 25 years of • Sreenivas’
Slide 23: Industry Landscape
Industry Landscape Section • Market Opportunity 03 • Factors Driving Industry Growth 22
Slide 24: Markets Opportunity (Global)
Markets Opportunity (Global) Pharmaceutical Environment Electronics Preclinical Food Testing Analytical Testing Testing Testing 14,580 14,340 36,250 9,320 7,430 3,990 25,330 (USD Mn) 9,740 Global 6,250 2,550 2025 | 2030 2024 | 2034 2025 | 2030 2025 | 2030 2023 | 2030 23
Slide 25: Markets Opportunity (Indian)
Markets Opportunity (Indian) Pharmaceutical Environment Electronics Preclinical Food Testing Analytical Testing Testing Testing 309 394 1,799 460 100 (USD Mn) Indian 185 293 211 832 50 2025 | 2030 2024 | 2030 2024 | 2033 2024 | 2030 2021 | 2028 24
Slide 26: Factors Driving Industry Growth
Factors Driving Industry Growth • Increasing demand for new drug • Surge in demand for certification innovations, growth in biologics and services of electrical & electronic vaccine products development, and increasing regulations in pharma and products, growing defence budgets biotech industry and
Slide 27: Our Competitive Advantage
Our Competitive Advantage Section • Our Position in the CRTO Landscape 04 • Our Strength 26
Slide 28: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape Pharma Analytical Clinical Research Electronics & Electricals • #1 in India • Among the most reputed CROs in • One of the leading labs in • Customers – 90% of India top 20 India Southern India • 36% revenues from overseas • 75% of revenues from overseas Food Testin
Slide 29: Our Strengths
Our Strengths Infrastructure Innovations Knowledge Unparalleled lab Continuous addition Multi-disciplinary, infrastructure in the of services and knowledgeable, skilled country. Gold LEED evolving excellence and trained certified Vivarium manpower Customer Centricity Compliance Technology Long term
Slide 30: Way Forward
Way Forward Section • Our Key Growth Drivers & Strategies 05 29
Slide 31: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable Core business Core operational Best markets strategies strategies practices Growth momentum Capacity expansions Operational excellence Good corporate governance in markets Service innovations Hiring right talent Risk management Growing d
Slide 32: Thank You
THANK YOU Vimta Labs Ltd. Registered Office Siva Kambhampati | Chief Financial Officer #142, IDA Phase 2 Cherlapally, Siva.Kambhampati@vimta.com Hyderabad Telangana, India. 500051 Ernst & Young Siddesh Chawan Advait Bhadekar NSE: VIMTALABS ISIN: INE579C01029 Siddesh.Chawan@in.ey.com Advait.Bhadekar@